To estimate the frequency and specificity of MSH2 germline mutations among patients with CRC in the real world, we systematically analyzed a consecutive CRC patient cohort that had been universally screened for LS in our previous study (22). This evidence concerns the gene MSH2 and colorectal carcinoma.